Thus because CETP has a large natural variability, and declines with progression to diabetes, understanding how this pathway may be augmented to improve exercise capacity with obesity may be a new therapeutic opportunity. This evidence concerns the gene CETP and obesity due to melanocortin 4 receptor deficiency.